Comparison of trimethoprim-sulfamethoxazole and ampicillin theraphy for shigellosis in ambulatory.
One-hundred seventy-four infants and children with acute diarrhea were treated as ambulatory patients with either ampicillin (100 mg/kg/day orally in four divided doses) or trimethoprim sulfamethoxazole (10 mg TMP and 50 mg SMX/KG/day orally in two divided doses). There were 65 patients with shigellosis. Responses of those treated with TMP/SMX and of those with susceptible Shigella treated with ampicillin were comparable. Patients with resistant organisms failed to respond to ampicillin. All Shigella, including ampicillin-resistant strains, were suseptible in vitro to TMP/SMX, and patients with ampicillin-resistant strains responded favorably to treatment with TMP/SMX. TMP/SMX appears to be the best, currently available drug for the treatment of shigellosis.
D000553:Ambulatory Care; D000667:Ampicillin / Q000627:therapeutic use*; D002648:Child; D004338:Drug Combinations; D004341:Drug Evaluation; D004405:Dysentery, Bacillary / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D010403:Penicillin Resistance; D013420:Sulfamethoxazole / Q000627:therapeutic use*; D013781:Texas; D014295:Trimethoprim / Q000627:therapeutic use*
D004338:Drug Combinations; D000667:Ampicillin; D014295:Trimethoprim; D013420:Sulfamethoxazole